Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. / Stride, Nis; Larsen, Steen; Hey-Mogensen, Martin; Sander, Kåre; Lund, Jens T; Gustafsson, Finn; Køber, Lars; Dela, Flemming.
I: European Journal of Heart Failure, Bind 15, Nr. 2, 02.2013, s. 150-7.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction
AU - Stride, Nis
AU - Larsen, Steen
AU - Hey-Mogensen, Martin
AU - Sander, Kåre
AU - Lund, Jens T
AU - Gustafsson, Finn
AU - Køber, Lars
AU - Dela, Flemming
PY - 2013/2
Y1 - 2013/2
N2 - Heart failure (HF) with left ventricular systolic dysfunction (LVSD) is associated with a shift in substrate utilization and a compromised energetic state. Whether these changes are connected with mitochondrial dysfunction is not known. We hypothesized that the cardiac phenotype in LVSD could be caused by reduced mitochondrial oxidative phosphorylation (OXPHOS) capacity and reduced mitochondrial creatine kinase (miCK) capacity. The study aim was to test mitochondrial OXPHOS capacity in LVSD myocardium compared with OXPHOS capacity in a comparable patient group without LVSD.
AB - Heart failure (HF) with left ventricular systolic dysfunction (LVSD) is associated with a shift in substrate utilization and a compromised energetic state. Whether these changes are connected with mitochondrial dysfunction is not known. We hypothesized that the cardiac phenotype in LVSD could be caused by reduced mitochondrial oxidative phosphorylation (OXPHOS) capacity and reduced mitochondrial creatine kinase (miCK) capacity. The study aim was to test mitochondrial OXPHOS capacity in LVSD myocardium compared with OXPHOS capacity in a comparable patient group without LVSD.
U2 - 10.1093/eurjhf/hfs172
DO - 10.1093/eurjhf/hfs172
M3 - Journal article
C2 - 23115323
VL - 15
SP - 150
EP - 157
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 2
ER -
ID: 44914716